GlassScriptPhysician profile
Evan K Daugherty
NPI 1487117198
$5,835.72
in general payments reported to CMS, 2019-2025
29 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $702 · 2023: $2,318 · 2024: $2,137 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,118 · Education: $15.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,117.71 |
| Education | $15.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $847.62 | 2022-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.42 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $622.03 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Genzyme Corporation | $602.19 | 2022-2025 | |
| Abbvie INC. | $539.26 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $454.02 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Ferring Pharmaceuticals INC. | $312.68 | 2022-2025 | Rebyota, Euflexxa |
| Boston Scientific Corporation | $204.55 | 2023-2024 | Resolution 360 Clip |
| Regeneron Healthcare Solutions, INC. | $200.01 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $175.87 | 2023 | |
| Celgene Corporation | $145.64 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $129.23 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $120.39 | 2024-2025 | |
| Pfizer INC. | $98.97 | 2023-2025 | |
| Madrigal Pharmaceuticals | $61.41 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $51.95 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $47.10 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $46.13 | 2022-2024 | |
| Lilly USA, LLC | $43.63 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2024 | Cyltezo |
| Exact Sciences Corporation | $35.23 | 2023 | Cologuard Collection Kit |
| Celltrion USA INC. | $33.18 | 2024-2025 | Vegzelma, Zymfentra |
| Sandoz INC. | $32.36 | 2023-2024 | Hyrimoz |
| Braintree Laboratories, INC. | $31.51 | 2023 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $19.12 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $17.95 | 2022 | |
| Organon LLC | $14.13 | 2024 | |
| Qol Medical, LLC | $13.29 | 2023 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.